Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| OnKure Therapeutics, Inc.OKUR · Entity 6550 | 10% owner | May 15, 2025 | May 19, 2025 |
| Oruka Therapeutics, Inc.ABIO · Entity 3781 | Director | January 30, 2024 | January 31, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
OnKure Therapeutics, Inc.
Report date May 15, 2025 · Filed May 19, 2025
Jointly reported with ACORN BIOVENTURES, L.P., ACORN CAPITAL ADVISORS GP, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,709,944 |
Reported balance
After 2025-05-15 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-05-15 · Purchase · Acquired 270,270 · Balance 1,709,944 F1: Shares held directly by Acorn Bioventures, L.P. ("Acorn"). Acorn Capital Advisors GP, LLC ("Acorn GP") is the general partner of Acorn. Anders Hove is the manager of Acorn GP. Each of Acorn GP and Mr. Hove disclaims beneficial ownership of disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Acorn Bioventures 2, L.P. | 1,129,730 |
Reported balance
After 2025-05-15 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2025-05-15 · Purchase · Acquired 1,129,730 · Balance 1,129,730 F2: Shares held directly by Acorn Bioventures 2, L.P. ("Acorn 2"). Acorn Capital Advisors GP 2, LLC ("Acorn GP 2") is the general partner of Acorn 2. Anders Hove is the manager of Acorn GP 2. Each of Acorn GP 2 and Mr. Hove disclaims beneficial ownership of disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares held directly by Acorn Bioventures, L.P. ("Acorn"). Acorn Capital Advisors GP, LLC ("Acorn GP") is the general partner of Acorn. Anders Hove is the manager of Acorn GP. Each of Acorn GP and Mr. Hove disclaims beneficial ownership of disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
F2: Shares held directly by Acorn Bioventures 2, L.P. ("Acorn 2"). Acorn Capital Advisors GP 2, LLC ("Acorn GP 2") is the general partner of Acorn 2. Anders Hove is the manager of Acorn GP 2. Each of Acorn GP 2 and Mr. Hove disclaims beneficial ownership of disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Oruka Therapeutics, Inc.
Report date January 30, 2024 · Filed January 31, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.64 · Expires 2034-01-30 | Direct | 6,000 |
Reported balance
After 2024-01-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-30 · Grant · Acquired 6,000 · Balance 6,000 F1: Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of January 30, 2024, subject to the Reporting Person continuing to provide Continuous Service (as defined in the 2020 Equity Incentive Plan) through such date. If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of January 30, 2024, subject to the Reporting Person continuing to provide Continuous Service (as defined in the 2020 Equity Incentive Plan) through such date. If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Inspire Medical Systems, Inc.
Report date May 07, 2018 · Filed May 10, 2018
Jointly reported with Amzak Health Investors, LLC, Kazma Michael D
Section 16 reporting ended · disclosed 2018-05-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,497,043 |
Last balance in matching sequence
After 2018-05-07 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2018-05-07 · Conversion · Acquired 1,372,043 · Balance 1,372,043 F1: Shares of Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation, as amended). These shares had no expiration date. F2: These shares are held of record by Amzak Health Investors, LLC ("Amzak Health"). Joyce Erony, a director of the Issuer, Michael D. Kazma, and Anders Hove are managers of Amzak Health and, as a result, have shared voting and dispositive power over the shares held by Amzak Health. Each of Ms. Erony and Mr. Hove disclaims beneficial ownership of the shares held by Amzak Health except to the extent of his or her proportionate pecuniary interest therein. Row 2 · 2018-05-07 · Purchase · Acquired 125,000 · Balance 1,497,043 F2: These shares are held of record by Amzak Health Investors, LLC ("Amzak Health"). Joyce Erony, a director of the Issuer, Michael D. Kazma, and Anders Hove are managers of Amzak Health and, as a result, have shared voting and dispositive power over the shares held by Amzak Health. Each of Ms. Erony and Mr. Hove disclaims beneficial ownership of the shares held by Amzak Health except to the extent of his or her proportionate pecuniary interest therein. |
| Series F Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-05-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-05-07 · Conversion · Disposed 9,124,088 · Balance 0 F1: Shares of Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation, as amended). These shares had no expiration date. F2: These shares are held of record by Amzak Health Investors, LLC ("Amzak Health"). Joyce Erony, a director of the Issuer, Michael D. Kazma, and Anders Hove are managers of Amzak Health and, as a result, have shared voting and dispositive power over the shares held by Amzak Health. Each of Ms. Erony and Mr. Hove disclaims beneficial ownership of the shares held by Amzak Health except to the extent of his or her proportionate pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation, as amended). These shares had no expiration date.
F2: These shares are held of record by Amzak Health Investors, LLC ("Amzak Health"). Joyce Erony, a director of the Issuer, Michael D. Kazma, and Anders Hove are managers of Amzak Health and, as a result, have shared voting and dispositive power over the shares held by Amzak Health. Each of Ms. Erony and Mr. Hove disclaims beneficial ownership of the shares held by Amzak Health except to the extent of his or her proportionate pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2025 Filed May 19, 2025 16:43 UTC | OnKure Therapeutics, Inc. OKUR · Entity 6550 | PurchaseCommon Stock | 1,129,730 | $1.85 | $2,090,000.50 |
DisclosureSEC source: 0000950170-25-074459 · ownership.xml · nonDerivative · entry 2 ACORN BIOVENTURES, L.P. · CIK 0001766853 · 10% owner ACORN CAPITAL ADVISORS GP, LLC · CIK 0001813692 · 10% owner Hove Anders D · CIK 0001365618 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Acorn Bioventures 2, L.P. Disclosed balance after: 1,129,730 F2 · ownership.direct: Shares held directly by Acorn Bioventures 2, L.P. ("Acorn 2"). Acorn Capital Advisors GP 2, LLC ("Acorn GP 2") is the general partner of Acorn 2. Anders Hove is the manager of Acorn GP 2. Each of Acorn GP 2 and Mr. Hove disclaims beneficial ownership of disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| May 15, 2025 Filed May 19, 2025 16:43 UTC | OnKure Therapeutics, Inc. OKUR · Entity 6550 | PurchaseCommon Stock | 270,270 | $1.85 | $499,999.50 |
DisclosureSEC source: 0000950170-25-074459 · ownership.xml · nonDerivative · entry 1 ACORN BIOVENTURES, L.P. · CIK 0001766853 · 10% owner ACORN CAPITAL ADVISORS GP, LLC · CIK 0001813692 · 10% owner Hove Anders D · CIK 0001365618 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,709,944 F1 · ownership.direct: Shares held directly by Acorn Bioventures, L.P. ("Acorn"). Acorn Capital Advisors GP, LLC ("Acorn GP") is the general partner of Acorn. Anders Hove is the manager of Acorn GP. Each of Acorn GP and Mr. Hove disclaims beneficial ownership of disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| January 30, 2024 Filed Jan 31, 2024 21:25 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | GrantStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001209191-24-002481 · doc4.xml · derivative · entry 1 Hove Anders D · CIK 0001365618 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2034-01-30 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of January 30, 2024, subject to the Reporting Person continuing to provide Continuous Service (as defined in the 2020 Equity Incentive Plan) through such date. If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested. Read SEC document |
| December 15, 2022 Filed Dec 19, 2022 21:23 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | GrantStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001209191-22-061911 · doc4.xml · derivative · entry 1 Hove Anders D · CIK 0001365618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2032-12-15 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of December 15, 2022. If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 00:07 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-21-003472 · doc4.xml · derivative · entry 1 Hove Anders D · CIK 0001365618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2031-01-12 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan, vesting in 36 equal monthly installments beginning as of December 21, 2020. If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested. Read SEC document |
| May 07, 2018 Filed May 10, 2018 01:19 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | ConversionSeries F Convertible Preferred Stock · Derivative | 9,124,088 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-031864 · a4.xml · derivative · entry 3 Amzak Health Investors, LLC · CIK 0001719184 · 10% owner Kazma Michael D · CIK 0001702237 · 10% owner Hove Anders D · CIK 0001365618 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,372,043 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation, as amended). These shares had no expiration date. F1 · derivative.exercise_date: Shares of Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation, as amended). These shares had no expiration date. F1 · derivative.expiration_date: Shares of Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation, as amended). These shares had no expiration date. F2 · ownership.direct: These shares are held of record by Amzak Health Investors, LLC ("Amzak Health"). Joyce Erony, a director of the Issuer, Michael D. Kazma, and Anders Hove are managers of Amzak Health and, as a result, have shared voting and dispositive power over the shares held by Amzak Health. Each of Ms. Erony and Mr. Hove disclaims beneficial ownership of the shares held by Amzak Health except to the extent of his or her proportionate pecuniary interest therein. Read SEC document |
| May 07, 2018 Filed May 10, 2018 01:19 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | PurchaseCommon Stock | 125,000 | $16.00 | $2,000,000.00 |
DisclosureSEC source: 0001104659-18-031864 · a4.xml · nonDerivative · entry 2 Amzak Health Investors, LLC · CIK 0001719184 · 10% owner Kazma Michael D · CIK 0001702237 · 10% owner Hove Anders D · CIK 0001365618 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,497,043 F2 · ownership.direct: These shares are held of record by Amzak Health Investors, LLC ("Amzak Health"). Joyce Erony, a director of the Issuer, Michael D. Kazma, and Anders Hove are managers of Amzak Health and, as a result, have shared voting and dispositive power over the shares held by Amzak Health. Each of Ms. Erony and Mr. Hove disclaims beneficial ownership of the shares held by Amzak Health except to the extent of his or her proportionate pecuniary interest therein. Read SEC document |
| May 07, 2018 Filed May 10, 2018 01:19 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | ConversionCommon Stock | 1,372,043 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-031864 · a4.xml · nonDerivative · entry 1 Amzak Health Investors, LLC · CIK 0001719184 · 10% owner Kazma Michael D · CIK 0001702237 · 10% owner Hove Anders D · CIK 0001365618 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,372,043 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation, as amended). These shares had no expiration date. F2 · ownership.direct: These shares are held of record by Amzak Health Investors, LLC ("Amzak Health"). Joyce Erony, a director of the Issuer, Michael D. Kazma, and Anders Hove are managers of Amzak Health and, as a result, have shared voting and dispositive power over the shares held by Amzak Health. Each of Ms. Erony and Mr. Hove disclaims beneficial ownership of the shares held by Amzak Health except to the extent of his or her proportionate pecuniary interest therein. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 22:32 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001209191-18-016685 · doc4.xml · derivative · entry 1 Hove Anders D · CIK 0001365618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2028-02-29 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the 2013 Amended and Restated Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of January 1, 2018. If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 21:47 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001209191-17-012755 · doc4.xml · derivative · entry 5 Hove Anders D · CIK 0001365618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-02-15 F5 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the 2013 Amended and Restated Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of February 16, 2017. If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.